Cargando…

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir

The discovery and development of fostemsavir (2), the tromethamine salt of the phosphonooxymethyl prodrug of temsavir (1), encountered significant challenges at many points in the preclinical and clinical development program that, in many cases, stimulated the implementation of innovative solutions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Tao, Kadow, John F., Meanwell, Nicholas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476988/ https://www.ncbi.nlm.nih.gov/pubmed/34602806 http://dx.doi.org/10.1007/s00044-021-02787-6

Ejemplares similares

Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment
por: Sevinsky, Heather, et al.
Publicado: (2017)

2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients
por: Moore, Katy P, et al.
Publicado: (2019)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
por: Anderson, Sarah-Jane, et al.
Publicado: (2021)

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
por: Lataillade, Max, et al.
Publicado: (2018)

Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis
por: Lagishetty, Chakradhar, et al.
Publicado: (2020)

Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts
por: Patil, Satish, et al.
Publicado: (2015)

Fostemsavir for HIV-1 infection
Publicado: (2022)

Temsavir Modulates HIV-1 Envelope Conformation by Decreasing Its Proteolytic Cleavage
por: Boutin, Marianne, et al.
Publicado: (2023)

Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action
por: Langley, David R, et al.
Publicado: (2015)

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
por: Bigirimana, Ferdinand, et al.
Publicado: (2023)

Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir
por: Prévost, Jérémie, et al.
Publicado: (2023)

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies
por: Boutin, Marianne, et al.
Publicado: (2022)

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
por: Rose, Ronald, et al.
Publicado: (2022)

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(®) Entry assay
por: Gartland, Margaret, et al.
Publicado: (2020)

The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex
por: Meanwell, Nicholas A., et al.
Publicado: (2018)

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
por: Ackerman, Peter, et al.
Publicado: (2021)

The pyridazine heterocycle in molecular recognition and drug discovery
por: Meanwell, Nicholas A.
Publicado: (2023)

Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
por: Aberg, Judith A., et al.
Publicado: (2023)

Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis
por: Lalezari, Jacob, et al.
Publicado: (2014)

HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis
por: Brinson, Cynthia, et al.
Publicado: (2014)

540 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis
por: Brinson, Cynthia, et al.
Publicado: (2014)

Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database
por: Gartland, Margaret, et al.
Publicado: (2021)

Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats
por: Chae, Kyung-Ae, et al.
Publicado: (2007)

Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
por: Muccini, Camilla, et al.
Publicado: (2022)

1574 Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis
por: Lalezari, Jacob, et al.
Publicado: (2014)

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug
por: Rais, Rana, et al.
Publicado: (2022)

547. Results of Patient-Reported Outcome Data From the Phase III BRIGHTE Study of Fostemsavir
por: Proudfoot, Clare, et al.
Publicado: (2018)

The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)
por: Meanwell, Nicholas A., et al.
Publicado: (2018)

1315. No Dose Adjustment of Metformin with Fostemsavir Coadministration Based on Mechanistic Static and Physiologically Based Pharmacokinetic Models
por: Nguyen, Dung N, et al.
Publicado: (2020)

Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition
por: Lai, Yen-Ting
Publicado: (2021)

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
por: Gartland, Margaret, et al.
Publicado: (2022)

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants
por: Moore, Katy, et al.
Publicado: (2019)

Green-adapted spectrophotometric determination of fostemsavir based on selective bromophenol blue extraction; reduction of hazardous consumption using computational calculations
por: Batubara, Afnan S., et al.
Publicado: (2023)

Simultaneous determination of 2-(3-hydroxy-5-phosphonooxymethyl-2-methyl-4-pyridyl)-1,3-thiazolidine-4-carboxylic acid and main plasma aminothiols by HPLC–UV based method
por: Piechocka, Justyna, et al.
Publicado: (2023)

Discovery of a Series of Potent and Selective Nucleotide Prodrug Inhibitors of Respiratory Syncytial Virus (RSV) Replication
por: Good, Steven, et al.
Publicado: (2017)

Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir
por: Patel, Mitesh, et al.
Publicado: (2014)

HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat
por: Zuwala, Kaja, et al.
Publicado: (2016)

Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids
por: Nair, Vasu, et al.
Publicado: (2015)

Ticlopidine in Its Prodrug Form Is a Selective Inhibitor of Human NTPDase1
por: Lecka, Joanna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1cdrt125iv1o613jq5a4vr992n